

ERITREA Support for Pentavalent Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Eritrea						
2. Grant number: 1821-ERI-04a-X / 07-ERI-08b-Y						
3. Date of Decision Letter: 23 March 2018						
4. Date of the Partnership Framework Agreement: 16 April 2013						
5. Programme title: New Vaccine Support (NVS), Pentavalent Routine						
6. Vaccine type: Pentavalent						
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 1 dose(s) per vial, LIQUID						
8. Programme duration¹: 2008 - 2021						
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)						
	2008-2017	2018	2019	2020	2021	Total ²
Programme Budget (US\$)	7,062,380 ³	181,000	332,500	349,000	366,500	8,291,380
10. Vaccine introduction grant (in US\$): A VIG of US\$100,000 was disbursed on 16 th March 2007.						
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴						
Type of supplies to be purchased with Gavi funds in each year	2008-2017		2018			
Number of Pentavalent vaccines doses			155,700			
Annual Amounts (US\$)	US\$7,062,380 ⁵		US\$181,000			
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.						
13. Self-procurement: N/A						

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<p>14. Co-financing obligations: Reference code: 1821-ERI-04a-X-C</p> <p>According to the co-financing policy, the Country falls within the group Initial self-financing.</p> <p>The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p>										
Type of supplies to be purchased with Country funds in each year	2018	2019	2020	2021						
Number of vaccine doses	32,500	63,300	66,500	69,800						
Value of vaccine doses (US\$)	US\$35,061	US\$66,452	US\$69,770	US\$73,257						
Total co-financing payments (US\$) (including freight)	US\$38,000	US\$71,500	US\$75,500	US\$79,000						
<p>15. Operational support for campaigns: Not applicable</p>										
<p>16. Additional reporting requirements:</p> <table border="1"> <thead> <tr> <th>Reports and other information</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.</td> <td>May</td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Secretariat</td> </tr> </tbody> </table>					Reports and other information	Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
Reports and other information	Due dates									
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May									
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat									
<p>17. Financial clarifications: N/A</p>										
<p>18. Other conditions: N/A</p>										

Signed by,
On behalf of Gavi



Hind Khatib-Othman
 Managing Director, Country Programmes
 23 March 2018